Contexte sectoriel
Exelixis Inc [EXEL]
Dernière mise à jour 24 Jun 2026 @ 16:00 (Exchange is closed)
Dernier : $52.87
2.98%
-0.82
GaG Algo Score™
v1.0
Court
-0.82
Moyen
1.62
Long
1.11
ACHAT
65.31%
rendement 5.91%
VENTE
60.00%
rendement -12.54%
Ligne
Données pivot
Statistiques pivot
| Métrique | Moyenne | Médiane | Écart type |
|---|---|---|---|
| Gain % | 10.22% | 10.22% | 0.00% |
| Perte % | N/A | N/A | N/A |
| Durée | 9.0d | 9d | 0.0d |
| Total des pivots trouvés | 2 |
| Segments gain/perte | 1 (1 Gain / 0 Perte) |
| Dernier pivot | Top @ $53.50 le 2026-06-11 |
| Variation depuis le dernier pivot | $-2.16 (-4.04%) |
Prévision du prochain pivot Dernier : $52.87
| Prochain type prévu | N/D |
| Prix prévu (moy.) | N/A |
| Prix prévu (médiane) | N/A |
| Fourchette de prix prévue (~68%) | N/A |
| Variation vers cible moyenne | N/A (N/A) |
| Date prévue (moy.) | 2026-06-20 |
| Plage de dates prévue (~68%) | 2026-06-20 - 2026-06-20 |
| Base | Insufficient historical loss data for prediction. and duration (Avg: 9.0 days, StdDev: 0.0 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Exelixis Inc edges lower, down -0.02%.
Exelixis Inc (EXEL) stock price held steady on Tuesday after the stock fell $-0.01000 (-0.02%) from the previous session on normal volume. The stock held up slightly better than the falling NASDAQ (-0.43% down). A total of 2.57M stocks were traded yesterday, valued at $132.17M, 930 037 shares less than the previous day (3 504 387 shares traded). This is near the average volume for the stock at 2.60M shares traded per day.
Exelixis Inc signals
There is no conclusive signals given from RSI. The price is above both the short- and long-term averages, and the short-term average is above the long-term average, confirming an established up-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (6.7%), medium- (6.7%), and long-term (6.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Exelixis Inc Support & Resistance Levels
The stock is approaching the closest resistance level at $51.50. approximately $0.160 (0.31%) away. Reacting down from resistance. Breaking above this level could signal further upside where next resistance level will be found at $51.9. On a fall back there will be support at $42.4 The dis das resistance s142.4 -
Exelixis Inc Evaluation
- Court score: -0.82
- Moyen score: 1.62
- Long score: 1.11
Flux des initiés
GetAGraph InsiderPower
Transactions
265
Force acheteuse
310.03M
Force vendeuse
310.79M
Fiabilité
100/100
Achat / vente
1.00
Corr. hist.
-0.60
Dernier signal
Sell 2026-06-03
Officer 133
Director 90
Executive 42
2026-06-01
Wyszomierski Jack L Director
Sell 3 925
2026-06-01
Eckhardt Sue Gail Director
Sell 9 812
2026-05-27
Papadopoulos Stelios Director
Buy 8 367
2026-05-27
Heyman Tomas J. Director
Buy 8 367
2026-05-27
Eckhardt Sue Gail Director
Buy 8 367
2026-05-27
Smith Julie Director
Buy 8 367
Positioning pressure
Short interest pressure
Short interest
11.08%
Of outstanding shares
Short float
13.02%
Of tradable float
Days to cover
12.35
Short interest divided by average volume
Squeeze probability
58.60%
-1.89% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
7
EPS misses
2
Avg. surprise
29.20%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-10-27 | - | - | - | - |
| Q2/2025 | 2025-08-05 | - | $0.620 | - | - |
| Q1/2025 | 2025-05-13 | $0.620 | $0.420 | 47.62% | 555.45M |
| Q4/2024 | 2025-02-11 | $0.550 | $0.510 | 7.84% | 566.76M |
| Q3/2024 | 2024-10-29 | $0.400 | $0.350 | 14.29% | 539.54M |
| Q2/2024 | 2024-08-06 | $0.770 | $0.300 | 156.67% | 637.18M |
| Q1/2024 | 2024-04-30 | $0.170 | $0.280 | -39.29% | 425.23M |
| Q4/2023 | 2024-02-06 | $0.270 | $0.210 | 28.57% | 479.65M |
Analyst view
Analyst targets
Consensus
$47.33
Median
$47.00
Low
$41.00
High
$54.00
News flow
Latest company news
Market coverage
zacks.com EXEL Down on Colorectal Cancer Study Data on Zanzalintinib Jun 23, 2026 zacks.com Here's Why Exelixis (EXEL) is a Strong Growth Stock Jun 23, 2026 businesswire.com Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer Jun 22, 2026 zacks.com Here's Why Exelixis (EXEL) is a Strong Value Stock Jun 19, 2026Company releases
Company context
Company profile
Bourse :
NASDAQ
Secteur :
Healthcare
Industrie :
Biotechnology
Currency
USD
Exelixis Inc operates as a biotechnology firm dedicated to combating cancer primarily focusing on the identification advancement and marketing of novel oncological treatments within the United States Its portfolio of commercially available therapeutics includes CABOMETYX tablets prescribed for individuals with advanced renal cell carcinoma who have previously undergone antiangiogenic treatment and COMETRIQ capsules utilized for managing progressive and metastatic medullary thyroid cancer Both CABOMETYX and COMETRIQ originate from cabozantinib a compound that inhibits several tyrosine kinases such as MET AXL RET and VEGF receptors Additionally Exelixis offers COTELLIC an MEK inhibitor employed in combination therapies for advanced melanoma and MINNEBRO an orally administered nonsteroidal selective mineralocorticoid receptor blocker approved for hypertension treatment in Japan The companys developmental pipeline features several promising candidates such as XL092 an oral tyrosine kinase inhibitor designed to target VEGF receptors MET AXL MER and other kinases crucial for cancer proliferation XB002 an antibodydrug conjugate containing a human monoclonal antibody against tissue factor TF intended for advanced solid tumors and nonHodgkins lymphoma and XL102 an orally available cyclindependent kinase 7 CDK7 inhibitor being developed for advanced or metastatic solid tumors Exelixis Inc maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities including Ipsen Pharma SAS Takeda Pharmaceutical Company Ltd F HoffmannLa Roche Ltd Redwood Bioscience Inc RP Scherer Technologies LLC Catalent Pharma Solutions Inc NBE Therapeutics AG Aurigene Discovery Technologies Limited Iconic Therapeutics Inc Invenra Inc StemSynergy Therapeutics Inc Genentech Inc BristolMyers Squibb Company and Daiichi Sankyo Company Limited Established in 1994 the company originally operated as Exelixis Pharmaceuticals Inc before rebranding to Exelixis Inc in February 2000 Its corporate headquarters are located in Alameda California
Navigation